Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.

By M. Boaz, S. Smetana, T. Weinstein, Z. Matas, U. Gafter, A. Iaina, A. Knecht, Y. Weissgarten, D. Brunner, M. Fainaru and 1 more. The Lancet, 2000

1,066 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Nephrology

View Paper: https://www.semanticscholar.org/paper/57f1466c7b8eade251b8d41285480902a4b56e2a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. M. Traber
2. T. Ikizler

In Nephrology

1. Richard J. Johnson
2. K. Sugamura
3. J. Keaney

Citations in the corpus

• The role of oxidative stress in atherosclerosis. (2009, result): “In the ASAP study (Antioxidant Supplementation in Atherosclerosis Prevention) a combination of a-tocopherol (272 IU/d) and ascorbic acid (500 mg/d) decreased carotid intimamedia thickness in hypercholesterolemic males.(1,46,47) In contrast to these positive outcomes, the remaining antioxidant supple”
• Chronic Conditions, Functional Limitations, and Special Health Care Needs of School-Aged Children Born With Extremely Low-Birth-Weight in the 1990s (2005, positive): “This was unlikely; 2 previous trials of secondary prevention that reported a benefit of vitamin E also used a natural source.(21,27) On the other hand, a previous trial of secondary prevention, which included high-risk primary prevention patients, used natural-source vitamin E and found no benefits ”
• Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. (2003, methodology): “The SPACE trial tested the effect of vitamin E (800 IUuday) on a combined cardiovascular endpoint in 196 HD patients with pre-existing CVD, and showed a significant benefit from vitamin E supplementation [22].”
• Vitamins C and E: Beneficial effects from a mechanistic perspective (2011, background): “[195] suggested that in the clinical trials where vitamin E has had benefit, the subjects consuming the placebo had higher incidences of cardiovascular disease and perhaps greater oxidative stress; examples include end-stage renal disease and heart transplant patients.”
• Oxidant Mechanisms in Renal Injury and Disease (2016, positive): “However, clinical trials have reported both beneficial results upon introduction of vitamin E analogs, including reduced risk of CKD (22, 92, 129), and, in contrast, an absence of any beneficial effects (109) and even enhancement of mortality (122).”
• Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “In one study, a reduction of cardiovascular events as an end point receiving oral vitamin E supplementation in CKD patients undergoing HD was demonstrated (129).”
• Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality (2005, background): “SPACE, 2000 (50) Israel Dialysis patients with CVD 69 65 800 WAVE, 2002 (51) United States, Canada Postmenopausal women with CAD 0 65 800”
• The European perspective on vitamin E: current knowledge and future research. (2002, background): “In addition, at least 2 smaller prospective clinical trials have been completed: the Secondary Prevention with Antioxidants of Cardiovascular disease in Endstage renal disease (SPACE) study (80) and the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study (81).”
• IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. (2005, background): “138 have been shown to both reduce cardiovascular events in dialysis patient”